TerSera’s ZOLADEX LA gains Health Canada approval for breast cancer

2024-05-08

交易

上市批准疫苗

TerSera’s ZOLADEX LA gains Health Canada approval for breast cancer

Preview

来源: Pharmaceutical Technology

The new dosing option of ZOLADEX is aimed at pre and perimenopausal women with an increased recurrence or advanced breast cancer risk. Credit: Gorodenkoff / Shutterstock.com.

TerSera has obtained Health Canada’s approval for a supplemental new drug submission for ZOLADEX LA (goserelin acetate) 10.8mg administered every 12 weeks to manage oestrogen receptor-positive (ER+) early breast cancer.

The new dosing option of ZOLADEX is aimed at pre and perimenopausal women with an increased recurrence or advanced breast cancer risk.

Since 1995, a monthly dose of ZOLADEX 3.6mg has been approved for breast cancer treatment.

The latest approval provides a three-month dosing alternative specifically for younger women with hormone-positive (HR+) breast cancer.

The approval of the 10.8mg dosage is supported by multiple international studies that assessed the efficacy and safety of goserelin for ovarian function suppression in premenopausal patients with HR+ breast cancer HR+ breast cancer.

See Also:Sobi’s Aspaveli obtains indication extension approval in Europe

Preview

来源: Pharmaceutical Technology

Anixa expands cancer vaccine collaboration with Cleveland Clinic

Preview

来源: Pharmaceutical Technology

ZOLADEX LA is now approved for breast cancer treatment in 60 countries, with additional regulatory reviews in progress.

It is also used to treat prostate cancer and specific benign gynaecological disorders.

ZOLADEX is an injectable luteinising hormone-releasing hormone agonist (LHRHa) currently available in 125 countries.

It was first approved in Canada in 1989 and comes as a 3.6mg implant for 28-day dosing or as a 10.8mg implant for dosing every 12 weeks.

TerSera chief medical officer Nancy Martin stated: “TerSera is committed to supporting the unique needs of young women with HR+ breast cancer HR+ breast cancer.